Bisphosphonates in the management of metastatic prostate cancer

Oncology

Volumn 65, Issue SUPPL. 1, 2003, Pages 5-11

  Heidenreich, Axel ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Androgen deprivation; Ibandronate; Osteoporosis; Pain management; Palliation; Prostate cancer; Zoledronate

Indexed keywords

ALENDRONIC ACID; ANTIANDROGEN; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; DOCETAXEL; ETIDRONIC ACID; IBANDRONIC ACID; NERIDRONIC ACID; OLPADRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; TAXANE DERIVATIVE; TILUDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

ADVANCED CANCER; ANEMIA; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER RECURRENCE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DOSIMETRY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERABILITY; EDEMA; FATIGUE; FEVER; FRACTURE; HUMAN; KIDNEY FAILURE; LOCAL THERAPY; MORBIDITY; MYALGIA; NONHUMAN; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PATHOLOGIC FRACTURE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; REVIEW; SPINAL CORD COMPRESSION; VERTIGO;

ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DIPHOSPHONATES; HUMANS; IMIDAZOLES; MALE; PAIN; PALLIATIVE CARE; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 0042914933     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000072485     Document Type: Review

References (56)

1. Carlin BC, Andriole GA: The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 2000 (suppl);88:2989-2994.
2. Parker SL, Tong T, Bolden S, Wingo PA: Cancer statistics, 1996. CA Cancer J Clin 1996;46:5-27.
3. Berrutti A, Dogliotti L, Bitossi R, Fasolis G, Gorzegno G, Bellina M, Torta M, Porpiglia F, Fontana D, Alberto A: Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: Predictive role of bone resorption and formation markers evaluated at baseline. J Urol 2000;164:1248-1253.
4. Clarke NW, McClure J, George NJ: Morphometric evidence for bone resorption and replacement in prostate cancer. Br J Urol 1991;74-81.
5. Goltzman D: Mechanisms of the development of osteoblastic metastases. Cancer 1997 (suppl);80:1581-1587.
6. Mundy GR: Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat Rev 2002;2:584-593.
7. Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA, Simons JW: Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995;1:944-949.
8. Marquart H, Lioubin MN, Ikeda T: Complete amino acid sequence of human transforming growth factor type β-2. J Biol Chem 1997;262:12127-12130.
9. Harris SE, et al: Effects of transforming growth factor β on bone nodule formation and expression of bone morphogenic protein 2, osteocalcin, osteopontin, alkaline phosphatase and type 1 collagen mRNA in long-term cultures of fetal rat calvarial osteoblasts. J Bone Min Res 1994;9:855-863.
10. Autzen P, Robson CN, Bjartell A, Malcolm AJ, Johnson MI, Neal DE, Hamdy FC: Bone morphogenic protein 6 in skeletal metastases from prostate cancer and other common human malignancies. Br J Cancer 1998;78:1219-1223.
11. Rabbani SA, Desjardins J, Bell AW, Banville D, Mazar A, Henkin J, Goltzman D: An amino-terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells. Biochem Biophys Res Commun 1990;173:1058-1064.
12. Cramer SD, Chen Z, Peehl DM: Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain: inactivation of PTHrP stimulated cAMP accumulation in mouse osteoblasts. J Urol 1996;156:526-531.
13. Iwamura M, Hellmann J, Cockett AT, Lilja H, Gershagen S: Alteration of the hormonal bioactivity of parathyroid hormone related protein as a result of limited proteolysis by prostate-specific antigen. Urology 1996;48:317-325.
14. Berrutti A, Dogliotti L, Tucci M, Tarabuzzi R, Fontana D, Angeli A: Metabolic bone disease induced by prostate cancer: Rationale for the use of bisphosphonates. J Urol 2001;166: 2023-2031.
15. Oefelein MG, Richuiti V, Conrad W, Seftel A, Bodner D, Goldman H, Resnick M: Skeletal fracture rate associated with androgen suppression induced osteoporosis: The clinical incidence and risk factors for patients with prostate cancer. J Urol 2001;166:1724-1728.
16. Townsend MF, Sanders WH, Northway RO, Graham SD: Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer 1997;79:545-550.
17. Mittan D, Lee S, Miller E, Perez RC, Basler JW, Bruder JM: Bone loss following hypogonadism in men with prostate cancer treated with GnRH Analogs. J Clin Endocrinol Metab 2002;87:3656-3661.
18. Peters JL, Fairney A, Kyd P, Patel A, Rogers S, Webster JJ, Vale JA, Witherow RON: Bone loss associated with the use of LHRH agonists in prostate cancer. Prostate Cancer Prostate Dis 2001;4:161-166.
19. Smith MR: Osteoporosis and other adverse body composition changes during androgen deprivation therapy for prostate cancer. Cancer Metastasis Rev 2002;21:159-166.
20. Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, Adami S, Weber K, Lorenc R, Pietschmann P, Vandromael K, Lombardi A: Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000;343:604-610.
21. Smith MR, Shasha D, Mansour R, Zinner N: Zometa increases bone mineral density in men undergoing androgen deprivation therapy for prostate cancer. Skeletal Complications of malignancy (abstract C8). Proc Third North American Symposium, Bethesda, 2002, pp 25-27.
22. Diamond TH, Winters J, Smith A, de Souza P, Kersley JH, Lynch WJ, Bryant C: The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade. Cancer 2001;92:1444-1450.
23. Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, Kanthoff PW, Finkelstein JS: Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001;345:989-991.
24. Moyad MA: Complementary therapies for reducing the risk of osteoporosis in patients receiving luteinizing hormone-releasing hormone treatment/orchiectomy for prostate cancer: A review and assessment of the need for more research. Urology 2002;59(suppl 4A):34-40.
25. Dearnaley DP, Sydes MR, on behalf of the MRC PRO5 collaboration: Preliminary evidence that oral clodronate delays symptomatic progression of bone metastases from prostate cancer: First results of the MRC pro5 trial. Proc Am Soc Clin Oncol 2001;20:174a.
26. Saad F, Gleason DM; Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B: A randomised, placebo-controlled trial of zoledronic acid in patients with hormone refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458-1468.
27. Canil CH, Tannock IF: Should bisphosphonates be used routinely in patients with prostate cancer metastatic to the bone. J Natl Cancer Inst 2002;94:1422-1423.
28. Hillner BE, Weeks JC, Desch CE, Smith TJ: Pamidronate in prevention of bone complications in metastatic breast cancer: A cost-effectiveness analysis. J Clin Oncol 2000;18:72-79.
29. Smith JA Jr: Palliation of painful bone metastases from prostate cancer using sodium etidronate: Results of randomised, prospective, double-blind placebo controlled study. J Urol 1989;141:85-87.
30. Adami S, Salvagno G, Guarrera G: Dichlormethylene-diphosphonate in patients with prostatic carcinoma metastatic to the skeleton. J Uro1985;134:1152-1154.
31. Vorreuther R: Bisphosphonates as an adjunct to palliative therapy of bone metastases from prostatic carcinoma. A pilot study on clodronate. Br J Urol 1993;72:792-796.
32. Cresswell SM, English PJ, Hall RR: Pain relief and quality-of-life assessment following intravenous and oral clodronate in hormone-escaped metastatic prostate cancer. Br J Urol 1995;76:360.
33. Kylmala T, Taube T, Tammela TL, Risteli L, Risteli J, Elomaa I: Concomitant i.v. and oral clodronate in the relief of bone pain - a double-blind placebo-controlled study in patients with prostate cancer. Br J Cancer 1997;76:939-942.
34. Heidenreich A, Hofmann R, Engelmann UH: The use of bisphosphonates for the palliative treatment of painful osseous metastasis due to hormone refractory prostate cancer. J Urol 2001;165:136-140.
35. Piga A, Bracci R, Ferretti B, Sandri P, Nortilli R, Acito L, Pancotti A, Di Furia L, Carle F, Cellerino R: A double blind randomized study of oral clodronate in the treatment of bone metastases from tumors poorly responsive to chemotherapy. J Exp Clin Cancer Res 1998;17:213-217.
36. Strang P, Nilsson S, Brandstedt S, Sehlin J, Borghede G, Varenhorst B, Bandman U, Borck L, Englund G, Selin L: The analgesic efficacy of clodronate compared with placebo in patients with painful bone metastases from prostatic carcinoma. Anticancer Res 1997;17:4717-4721.
37. Coleman RE, Ourohit OP, Vinholes JJ, Zekri J: High-dose pamidronate: Clinical and biochemical effects in metastatic bone disease. Cancer 1997;80 (suppl):1652-1660.
38. Lipton A, Glover D, Harvey H, Grabelsky S, Zelenakas K, Macerata K, Seaman J: Pamidronate in the treatment of bone metastases: Results of 2 dose ranging trials in patients with breast and prostate cancer. Ann Oncol 1994; 5(suppl):S31-S35.
39. Heidenreich A, Elert A, Hofmann R: Ibandronate in the treatment of prostate cancer associated painful osseous metastases. Prostate Cancer Prostatic Dis 2002;5:231-235.
40. 186Re-etidronate in hormone-resistant prostate cancer patients with painful bone $metastases. Placebo Controlled Rhenium Study. J Nucl Med 2002;43:1150-1156.
41. Mannix K, Ahmedzai SH, Anderson H, Bennett M, Lloyd-Williams, Wilcock A: Using bisphosphonates to control pain of bone metastases: Evidence-based guidelines for palliative care. Palliat Med 2000;14:455-461.
42. Lee MV, Fong EM, Singer FR, Guenette RS: Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 2001;61:2602-2608.
43. Boissier S, Magnetto S, Frappart L, Cuzin B, Ebetino FH, Delmas PD, Clezardin P: Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralised and mineralised bone extracellular matrices. Cancer Res 1997;57:3890-3894.
44. Stearns ME, Wang M: Alendronate blocks metalloproteinase secretion and bone collagen I release by PC-3 ML cells in SCID mice. Clin Exp Metastasis 1998;16:693-702.
45. Stearns ME: Alendronate blocks TGF-beta 1 stimulated collagen 1 degradation by human prostate PC-3 ML cells. Clin Exp Metastasis 1998;16:332-339.
46. Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M, Delmas P, Delaisse JM, Clezardin P: Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000;60:2949-2954.
47. Yu-Cheng S, Geldorf AA, Newling DWW, Rao BR: Progression delay of prostate tumor skeletal metastasis effects by bisphosphonates. J Urol 1992;148:1270-1273.
48. Lee YP, Schwarz EM, Davies M, Jo M, Gates J, Zhang X, Wu J, Lieberman JR: Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model. Cancer Res 2002;62:5564-5570.
49. Fischer C, Neudert M, Krempien B, Bauss F, Seibel MJ: Ibandronic acid prevents the development and induces remission of bone metastasis in a nude rat model of human breast cancer. Proc ASCO 2001;20:84a.
50. Yi B, Williams PJ, Niewolna M, Story B, Mundy GR, Yoneda T: Reduction of osteoblastic bone metastases by the bisphosphonate ibandronate. J Bone Min Res 1999;14(suppl 1):SA055.
51. Paterson AHG: The potential role of bisphosphonates as adjuvant therapy in the prevention of bone metastases. Cancer 2000;88:3038-3046.
52. Diehl I, Solomeyer EP, Costa S, Gollan C, Goerner R, Wallwiener D: Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998;339:357-363.
53. Saarto T, Blomqvist C, Virkkunen P, Elomaa I: Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer: 5-year results of a randomized controlled trial. J Clin Oncol 2001;19:10-17.
54. Diehl IJ: Bisphosphonates in the prevention of bone metastases: Current evidence. Semin Oncol 2001;28(suppl 6):75-80.
55. Stearns ME, Wang M: Effects of alendronate and taxol on PC3 ML cell bone metastases in SCID mice. Invasion Metastasis 1996;16:116-131.
56. Magnetto S, Boissier S, Delmas PD, Clezardin P: Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. Int J Cancer 1999;83:263-269.